In re Novartis and Par Antitrust Litig., No. 18-cv-04361 (S.D.N.Y.)
In the Exforge case, Faruqi & Farqui represents a pharmaceutical wholesaler and a proposed class of direct purchasers of the hypertension drug, Exforge. The complaint alleges that Novartis entered into a reverse payment agreement with Par to delay Par’s generic launch. In exchange, Novartis promised not to launch an authorized generic version of Exforge for the first 180 days Par was on the market.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Joseph T. Lukensjlukens@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Peter Kohnpkohn@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
685 Third Avenue 26th Floor New York, New York10017 (212) 983-9330 (877) 247-4292 (212) 983-9331
10866 Wilshire Boulevard Suite 1470 Los Angeles, California90024 (424) 256-2884 (424) 256-2885
3565 Piedmont Road NE Building Four, Suite 380 Atlanta, Georgia30305 (404) 847-0617 (404) 506-9534